Day: April 20, 2022

OTTAWA, April 20, 2022 (GLOBE NEWSWIRE) — Cornerstone Capital Resources Inc. (“Cornerstone” or “the Company”) (TSXV:CGP) (OTC:CTNXF) (FWB:GWN1) is pleased to announce the results of the Pre-Feasibility Study (“PFS”) for the Cascabel copper-gold porphyry joint venture project in northern Ecuador in which Cornerstone has a 15% interest financed through to completion of a feasibility study and repayable out of Cornerstone’s share of project earnings, plus 6.85% of the shares of joint venture partner and Project operator SolGold Plc (“SolGold”), for a total direct and indirect interest in Cascabel of 20.8%. The PFS confirms the Cascabel project’s potential to be a large, low-cost, and long-life mining operation that is based on achievable, proven, and tested mining and processing assumptions. Once constructed, Cascabel is expected...

MAJURO, Marshall Islands, April 20, 2022 (GLOBE NEWSWIRE) — GasLog Partners LP (“GasLog Partners” or the “Partnership”) (NYSE: GLOP) today announced that its financial results for the first quarter of 2022 will be released before the market opens on Thursday, April 28, 2022. GasLog Partners will host a conference call to discuss its results for the first quarter of 2022 at 8.30 a.m. EDT (3.30 p.m. EEST) on Thursday, April 28, 2022. The Partnership’s senior management will review the operational and financial performance for the period. Management’s presentation will be followed by a Q&A session. The dial-in numbers for the conference call are as follows: +1 866 374 5140 (USA)+44 20 3100 4191 (United Kingdom)+33 1 72 25 67 60 (France)+852 800 9337 52 (Hong Kong)+47 2396 4173 (Oslo) Conference ID: 90159316 A live webcast of...

Global crypto leader sees a bright future for Ethereum and begins to expand its digital product offering globally TORONTO, April 20, 2022 (GLOBE NEWSWIRE) — One year after launching the world’s first Ether spot ETF (Purpose Ether ETF; TSX ticker: ETHH), Purpose Investments Inc. (Purpose) today launched Purpose Crypto Corner, a new cryptocurrency hub on its website to help educate investors and advisors of all experience levels with digital assets. Purpose is also preparing to launch the first spot Bitcoin ETF in Australia with Cosmos Asset Management (Cosmos AM) for a target date of April 27. “We launched Purpose Ether ETF to give retail and institutional investors an easy way to access this amazing asset. Since launching, we’ve seen Ether’s price rise and fall, but despite its volatility, our long-term outlook is extremely optimistic....

New services include pathogen identification, microbiome profiling and rapid turnaround sequencing of clinical isolates ROCKVILLE, Md., April 20, 2022 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced today that its subsidiary, Ares Genetics (“Ares”), which strives to become a leader in bacterial genomics and AI-powered prediction of antimicrobial resistance (AMR), is commercially launching a series of new genome sequencing and analysis services globally.  In March 2022, the WHO emphasized the critical importance of microbial genome sequencing for pandemic preparedness in its new 10-year strategy1 for the global genomic surveillance of pathogens with pandemic and epidemic potential. To help...

VANCOUVER, British Columbia, April 20, 2022 (GLOBE NEWSWIRE) — Prosper Gold Corp. (“Prosper” or the “Company”) (TSXV:PGX) is pleased to announce that it has entered into a non-binding letter of intent (the “LOI”) dated April 20th, 2022 with CAVU Mining Corp. (“CAVU”) (CNSX: CAVU), a company incorporated under the laws of British Columbia, to grant CAVU the right to earn and acquire Prosper’s 51% interest (the “Option”) in the Star Project located in the province of British Columbia (the “Proposed Transaction”). Under the terms of the LOI, CAVU may exercise the Option by: (i) issuing 1,250,000 common shares in the capital of CAVU to Prosper within seven days after execution of the Definitive Agreement (defined below) (the “Effective Date); and (ii) making cash payments to Prosper in the following amounts:$100,000 within seven...

*** David Reardon, Luigi Naldini, Brad Loncar *** MILAN, Italy and NEW YORK, April 20, 2022 (GLOBE NEWSWIRE) — Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, announced it will hold a webinar entitled “Expert Perspectives: Immuno Gene & Cell Therapy for the Treatment of Solid Tumors” on Thursday, April 28, 2022 at 8:00 AM EDT / 2:00 PM CET. In this fireside chat, Genenta is delighted to bring together renowned neuro-oncologist David Reardon, MD (Harvard Medical School, Dana-Farber Cancer Institute) and Professor Luigi Naldini, MD, PhD (San Raffaele Telethon Institute for Gene Therapy), considered by many as the “father” of lentiviral gene therapy to discuss the potential application of immuno...

Clinical benefit again observed for OTO-413 versus placebo for multiple efficacy endpoints based on responder analysis at both Days 57 and 85 Results support clinical activity and tolerability findings from previous Phase 1/2 trial Enrollment in higher dose cohorts is ongoing with results expected in second half of 2022 Otonomy expects to initiate full dose-ranging Phase 2 efficacy trial by the end of 2022 Management will review results during a conference call today at 8:30 a.m. ETSAN DIEGO, April 20, 2022 (GLOBE NEWSWIRE) — Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced positive top-line results from the Phase 2a clinical trial of OTO-413 in subjects with hearing loss. The randomized, double-blind, placebo-controlled trial...

ZURICH, Switzerland, April 20, 2022 (GLOBE NEWSWIRE) — Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (OTCQB: ACHKF; SIX: ACHI; ISIN CH0522213468) (“Achiko”, the “Company”) announces the completion of an Equity Subscription Agreement (“ESS”) with the institutional investor RiverFort Global Opportunities PCC Limited (“RiverFort”) for the next thirty six months. The agreement provides for up to USD$10.5 million to help finance the production of AptameX™ in Indonesia and the expansion of the business operations for the continued combating of the spread and impact of Covid-19 as well as for other contemporary diagnostics solutions beyond Covid-19. The facility was arranged by the FCA regulated intermediary RiverFort Global Capital Limited based in London. In addition to the ESS, RiverFort have entered into an unsecured loan...

— Company to Host Conference Call and Webcast on May 11, 2022, at 8:00 a.m. ET SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., April 20, 2022 (GLOBE NEWSWIRE) — Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that it will report financial results and corporate updates for the three months ended March 31, 2022, after the closing of the U.S. equity markets on May 10, 2022. The Company will host a live conference call and webcast on May 11, 2022, at 8:00 a.m. ET. Conference Call and Webcast Information Listeners may access the live webcast by visiting the Company’s website at http://ir.zailaboratory.com. Participants must register in advance of the conference call. Details are as follows:Registration Link: http://apac.directeventreg.com/registration/event/5185688   Conference...